MedPath

Daily Wear Comparison of Enhanced and Non-Enhanced Silicone Hydrogel Lenses

Not Applicable
Completed
Conditions
Myopia
Interventions
Device: Lotrafilcon A Commercial Contact Lens
Device: Lotrafilcon A Experimental Contact Lens
Registration Number
NCT00813982
Lead Sponsor
CIBA VISION
Brief Summary

The purpose of this study is to compare an experimental contact lens with a currently marketed contact lens.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Able to wear contact lenses for a minimum of 5 days a week, at least 8 hours a day
  • On exam have ocular findings that are considered normal and would not prevent the safe wear of contact lenses
  • Other protocol-defined inclusion/exclusion criteria may apply
Exclusion Criteria
  • Requires concurrent ocular medication
  • Eye injury or surgery within twelve weeks immediately prior to enrollment
  • Evidence of systemic or ocular abnormality, infection, or disease likely to affect successful wear of contact lenses or use of their accessory solutions
  • Any active corneal infection
  • Any use of medications for which contact lens wear would be contraindicated
  • History of corneal refractive surgery
  • Wears toric contact lenses
  • Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Commercial Lotrafilcon A Contact LensLotrafilcon A Commercial Contact LensLotrafilcon A commercial contact lens randomly assigned to one eye
Experimental Lotrafilcon A Contact LensLotrafilcon A Experimental Contact LensLotrafilcon A experimental contact lens randomly assigned to one eye
Primary Outcome Measures
NameTimeMethod
Overall Vision1 week

Overall vision was interpreted by the subject and recorded on a questionnaire as a single, retrospective evaluation of 1-week wear time. Overall vision was evaluated by eye and rated on a 10-point scale, with 1 being poor and 10 being excellent.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath